Astellas, XenoPort ink sales pact Astellas Pharma Inc. reached an agreement Thursday with XenoPort Inc., a U.S. pharmaceutical company, giving it exclusive rights to sell in Japan and five other Asian markets a painkiller being developed by the U.S. firm, the two companies said.